WO2005049860A3 - Methodes et analyses diagnostiques et therapeutiques - Google Patents

Methodes et analyses diagnostiques et therapeutiques Download PDF

Info

Publication number
WO2005049860A3
WO2005049860A3 PCT/EP2004/011961 EP2004011961W WO2005049860A3 WO 2005049860 A3 WO2005049860 A3 WO 2005049860A3 EP 2004011961 W EP2004011961 W EP 2004011961W WO 2005049860 A3 WO2005049860 A3 WO 2005049860A3
Authority
WO
WIPO (PCT)
Prior art keywords
assays
diagnostic
therapeutic methods
methods
susceptibility
Prior art date
Application number
PCT/EP2004/011961
Other languages
English (en)
Other versions
WO2005049860A2 (fr
Inventor
Tomas Olsson
Fredrik Piehl
Olle Lidman
Maria Jansson
Original Assignee
Karolinska Innovations Ab
Tomas Olsson
Fredrik Piehl
Olle Lidman
Maria Jansson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karolinska Innovations Ab, Tomas Olsson, Fredrik Piehl, Olle Lidman, Maria Jansson filed Critical Karolinska Innovations Ab
Publication of WO2005049860A2 publication Critical patent/WO2005049860A2/fr
Publication of WO2005049860A3 publication Critical patent/WO2005049860A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne l'association d'allèles du gène mhc2ta ou CIITA à la sensibilité à une maladie ; des méthodes de détermination de la sensibilité chez des individus ; des analyses d'agents thérapeutiques ; et des traitements, en particulier associés à des troubles inflammatoires et auto-immuns, de type infarctus du myocarde aigu, polyarthrite rhumatoïde et sclérose en plaques.
PCT/EP2004/011961 2003-11-05 2004-10-22 Methodes et analyses diagnostiques et therapeutiques WO2005049860A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US51775903P 2003-11-05 2003-11-05
US60/517,759 2003-11-05
US60782704P 2004-09-08 2004-09-08
US60/607,827 2004-09-08

Publications (2)

Publication Number Publication Date
WO2005049860A2 WO2005049860A2 (fr) 2005-06-02
WO2005049860A3 true WO2005049860A3 (fr) 2005-11-10

Family

ID=34623067

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/011961 WO2005049860A2 (fr) 2003-11-05 2004-10-22 Methodes et analyses diagnostiques et therapeutiques

Country Status (1)

Country Link
WO (1) WO2005049860A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0648836A1 (fr) * 1993-08-26 1995-04-19 Bernard François Prof. Mach Transactivateur du complexe majeur d'histomcompatibilité de la classe II et ses utilisations
US5672473A (en) * 1994-08-24 1997-09-30 President And Fellows Of Harvard College Methods of identifying compounds useful for treating autoimmune diseases
WO2001066800A2 (fr) * 2000-03-07 2001-09-13 Whitehead Institute For Biomedical Research Polymorphismes humains a nucleotide unique
US20020151691A1 (en) * 1997-04-22 2002-10-17 Bernard Mach Nucleic acid sequences of ciita genes which can be involved in controlling and regulating the expression of genes encoding mhc type ii molecules, and their use, in particular as drugs.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0648836A1 (fr) * 1993-08-26 1995-04-19 Bernard François Prof. Mach Transactivateur du complexe majeur d'histomcompatibilité de la classe II et ses utilisations
US5672473A (en) * 1994-08-24 1997-09-30 President And Fellows Of Harvard College Methods of identifying compounds useful for treating autoimmune diseases
US20020151691A1 (en) * 1997-04-22 2002-10-17 Bernard Mach Nucleic acid sequences of ciita genes which can be involved in controlling and regulating the expression of genes encoding mhc type ii molecules, and their use, in particular as drugs.
WO2001066800A2 (fr) * 2000-03-07 2001-09-13 Whitehead Institute For Biomedical Research Polymorphismes humains a nucleotide unique

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BONTRON S ET AL: "Two novel mutations in the MHC class II transactivator CIITA in a second patient from MHC class II deficiency complementation group A.", HUMAN GENETICS. APR 1997, vol. 99, no. 4, April 1997 (1997-04-01), pages 541 - 546, XP002322239, ISSN: 0340-6717 *
DZIEMBOWSKA MAGDA ET AL: "Three novel mutations of the CIITA gene in MHC class II-deficient patients with a severe immunodeficiency.", IMMUNOGENETICS. FEB 2002, vol. 53, no. 10-11, February 2002 (2002-02-01), pages 821 - 829, XP002322240, ISSN: 0093-7711 *
RASMUSSEN H B ET AL: "Genetic susceptibility to multiple sclerosis: detection of polymorphic nucleotides and an intron in the 3' untranslated region of the major histocompatibility complex class II transactivator gene.", HUMAN IMMUNOLOGY. APR 2001, vol. 62, no. 4, April 2001 (2001-04-01), pages 371 - 377, XP002322238, ISSN: 0198-8859 *
SARTORIS SILVIA ET AL: "Analysis of CIITA encoding AIR-1 gene promoters in insulin-dependent diabetes mellitus and rheumatoid arthritis patients from the Northeast of Italy: Absence of sequence variability", HUMAN IMMUNOLOGY, vol. 61, no. 6, June 2000 (2000-06-01), pages 599 - 604, XP002322241, ISSN: 0198-8859 *
STEIMLE V ET AL: "COMPLEMENTATION CLONING OF AN MHC CLASS II TRANSACTIVATOR MUTATED IN HEREDITARY MHC CLASS II DEFICIENCY (OR BARE LYMPHOCYTE SYNDROME)", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 75, no. 1, 8 October 1993 (1993-10-08), pages 135 - 146, XP002051559, ISSN: 0092-8674 *

Also Published As

Publication number Publication date
WO2005049860A2 (fr) 2005-06-02

Similar Documents

Publication Publication Date Title
Chai et al. LOX-1+ PMN-MDSC enhances immune suppression which promotes glioblastoma multiforme progression
Oz-Levi et al. Mutation in TECPR2 reveals a role for autophagy in hereditary spastic paraparesis
Sharma et al. Large-scale replication and heterogeneity in Parkinson disease genetic loci
Nazé et al. Mutation analysis and association studies of the ubiquitin carboxy-terminal hydrolase L1 gene in Huntington's disease
EP2292758A3 (fr) Utilisations de cytokine de mammifère, réactifs associés
EP1583771A4 (fr) Polymorphismes genetiques associes a l'infarctus du myocarde, techniques de detection et utilisations de ceux-ci
WO2005016893A3 (fr) Methodes de traitement ou de prevention de maladies auto-immunes a l'aide de composes de 2,4-pyrimidinediamine
AU2002257162A1 (en) Humanized antibodies
WO2005079363A3 (fr) Agents therapeutiques a base d'aptameres utiles dans le traitement de troubles lies a un complement
EP2623602A3 (fr) Agents thérapeutiques à base d'aptamères utiles dans le traitement de troubles lies à un complément
NZ597779A (en) Treatment of inflammatory diseases using placental stem cells
Liu et al. IL-8–251T/A and IL-12B 1188A/C polymorphisms are associated with gout in a Chinese male population
WO2005072151A3 (fr) Marqueurs genetiques apoe associes a l'age de l'apparition de la maladie d'alzheimer
Marasini et al. Polymorphism of the fractalkine receptor CX3CR1 and systemic sclerosis‐associated pulmonary arterial hypertension
WO2006003520A3 (fr) Gene de predisposition a l'autisme humain codant pour un facteur de transcription et ses utilisations
WO2005049860A3 (fr) Methodes et analyses diagnostiques et therapeutiques
WO2005072152A3 (fr) Marqueurs genetiques apoc1 associes a la periode d'apparition de la maladie d'alzheimer
WO2005019474A3 (fr) Gene humain de susceptibilite a l'autisme et ses utilisations
Ha et al. A novel missense mutation of keratin 17 gene in a chinese family with steatocystoma multiplex
Bhanushali et al. Homozygous c. 1160C> T (P38L) in the MECP2 gene in a female Rett syndrome patient
WO2007071437A3 (fr) Compositions et méthodes pour traiter des troubles inflammatoires
Matsubara et al. T+ 31C polymorphism (M235T) of the angiotensinogen gene and home blood pressure in the Japanese general population: the Ohasama Study
Nursal et al. Angiotensin converting enzyme gene insertion/deletion variant and familial Mediterranean fever-related amyloidosis
EP1721972A4 (fr) Proteine mutante a domaine de liaison a l'adn de proteine telomerique trf2, mutant d'adn telomerique et utilisation de structure complexe de domaine de liaison de l'adn trf2 avec adn a double brin
Peddareddygari et al. Analysis of the interleukin-1 receptor antagonist gene variable number tandem repeats in ischemic stroke

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase